Healthcare
Kotak Alt funds Matrix founder's buyout of Viatris API business
Kotak Alternate Asset Managers has announced a Rs 1,445 crore investment in the acquisition of Viatris' active pharmaceutical ingredient (API) business by Matrix Laboratories founder Nimmagadda Prasad. The investment was made through Kotak Strategic Situations Fund II, as stated in a news release on Tuesday. However, specific details regarding the funding structure were not disclosed.
Viagra may improve brain functions, prevent dementia: Oxford Study
Sildenafil, known as Viagra, may help prevent memory-related problems by improving cerebral blood flow and blood vessel function, reducing the risk of vascular dementia. A University of Oxford study, highlighted by Dr. Praveen Gupta and Dr. Manjari Tripathi, shows promise but requires further research. Vascular dementia, affecting 40% of India's 5.3 million dementia patients, differs from Alzheimer's disease.
Human death from bird flu: What is bird flu? Signs, treatments, precautions
A 59-year-old man in Mexico City who contracted a subtype of bird flu has died in Mexico City, the World Health Organization said. The man, who had prior health complications died in hospital on April 24. This marks the first laboratory-confirmed human case of infection with an influenza A (H5N2) virus reported globally and the first avian H5 virus infection in a person reported in Mexico, the WHO said. "Although the source of exposure to the virus in this case is currently unknown, A (H5N2) viruses have been reported in poultry in Mexico," the WHO said.
CX Partners buys controlling stake in fertility centre Sabine
Founded in 2010, Sabine's Muvattupuzha hospital draws couples from across Kerala for IVF treatment that helps individuals or couples get pregnant. On an average, Sabine does about 500-600 IVF cycles per month, or about 42%-45% of all IVF procedures in Kerala.
Mankind Pharma in race with PEs to buy BSV Group at possible valuation of Rs 13,000 crore
Warburg Pincus, ChrysCapital, TPG, Blackstone, EQT, Mankind Pharma, and Dr Reddy's Laboratories are competing to acquire BSV Group, a biopharma firm specializing in women's health and critical care products, indicating a trend of consolidation in the domestic pharma sector. Mankind, Dr. Reddy’s, and Blackstone have evaluated BSV at different times, including before Advent's acquisition.
ET Analysis: Indian hospital chains report revenue growth & expansion plans amidst regulatory concerns
Leading hospital chains in India have reported improved average revenue per operating bed (ARPOB) and profitability in the latest quarter, driven by better payer mix and cost control measures. Expansion plans are underway, with a focus on markets like Bengaluru and Mumbai, through asset-light models. Adjacent businesses such as diagnostics, virtual care, and digital healthcare platforms are also seeing growth. However, regulatory proposals to rationalize rates may pose risks to sector valuations.
Govt issues guidance paper to strengthen vaccine companies' reporting of adverse events
The new report released last week aims to provide guidance to the manufacturers and importers of vaccines in the country so as to strengthen their AE/AEFI (adverse events following immunisation) monitoring and reporting and pharmacovigilance department to ensure patient safety.
Organon appoints Vivek Soares as country lead for India, South Asia
US-based healthcare firm Organon announced Vivek Soares as the new country lead for India and South Asia, bringing over 20 years of biopharmaceutical experience. Soares, previously with Organon Thailand, will succeed Anjan Sen, pivotal in establishing Organon's India operations. Soares aims to drive growth in the region, working towards a healthier future for women.
US-based Zeda plans to raise up to $200 million for India foray
US-based Zeda Holdings plans to raise $200 million for its India expansion, led by CEO Shri Shetty. The company uses 3D printing for orthopaedic implants.
Medtronic appoints Mandeep Singh Kumar as Vice President of India business
Kumar brings over 25 years of experience in the healthcare, pharmaceutical, and medical technology sectors. His expertise includes strategy development, execution, commercial excellence, and team building. Prior to joining Medtronic, Kumar served as country leader with Intuitive India, where he focused on expanding patient access, building an ecosystem for robotic-assisted surgery, and implementing customer robotic programmes.
Tata Capital Healthcare Fund invests $20 million in Orbicular Pharmaceutical Technologies
The specialty generics has a market size of $60 billion and is rapidly expanding, driven by increasing demand for cost-effective alternatives to complex and high-cost branded medications. “Under the able leadership of Dr. M.S. Mohan, Orbicular has developed a strong product pipeline for the regulated markets," said Visalakshi Chandramouli, managing partner, Tata Capital Healthcare Fund.
Must Watch
Shedding light on weight loss struggles among diabetics
Diabetes cases in India are rising, with 101 million individuals affected according to ICMR- INDIAB data. The International Diabetes Federation projects a 46% increase in global diabetes cases by 2045.
Delhi hospital fire: How unchecked private nursing homes thrive amid high costs & poor infra
The high costs of medical care at private corporate hospitals in Delhi, combined with inadequate infrastructure at government facilities, have led to a significant increase in the demand for private nursing homes. Unfortunately, these facilities often disregard regulations, with little effort from the administration to ensure compliance and accountability.
Fortis lines up Rs 1,300 cr capex to expand existing hospitals
Fortis Healthcare is investing up to Rs 1,300 crore in expanding capacities at existing hospitals over the next few years, according to a senior company executive. The healthcare provider aims to add around 2,200 beds over the next few years.
Chinese scientists develop cure for diabetes, insulin patient becomes medicine-free in just 3 months
Chinese scientists achieve diabetes cure through innovative cell therapy, detailed in Cell Discovery. Patient, treated in July 2021, no longer requires insulin after eleven weeks, and is now medication-free for 33 months. The breakthrough, praised by Timothy Kieffer, signifies a major advancement in diabetes treatment. This novel approach utilizes the body's regenerative abilities and could alleviate China's healthcare burden. Further studies are needed for validation.
